Table 4.
Summary of data from main studies on rapid daratumumab infusion.
| Study | Study type | Number of patients | Rapid infusion protocol | IRRs/AEs*, n (%) |
|---|---|---|---|---|
| Barr et al. (9) | Prospective, single center | 28 | 90 minutes: 20% of the dose in 30 minutes (200 mL/hr), 80% in 60 minutes (450 mL/hr) after >2 infusions | - No IRRs - 1 (3%) G2 hypertension |
| Hamadeh et al. (10) | Retrospective, single center | 53 | Same as above | - 1 (2%) G2 chills and rigors |
| Gozzetti et al. (11) | Prospective, single center | 39 | Same as above | - No IRRs |
| Lombardi et al. (12) | Prospective, single center | 25 | Same as above | - 2 (8%) G1 hypotension - 2 (8%) G1 hypertension |
| Patel et al. (13) | Retrospective, single center | 35 | Same as above | - 1 (3%) G1 IRR |
| Gordan et al. (14) | Retrospective, single center | 147 | 110 minutes, after >2 infusions | - No IRRs |
*Refers to IRRs/AEs occurred during the rapid infusion.
IRRs, infusion-related reactions; AEs, adverse events; n, number; G, grade.